Green biotechnology for sustainable pharmaceutical products

Technically speaking, biofuels and biobased bulk chemicals are low-hanging fruits, but higher-value and more complicated compounds are thought to have a greater economic and ecological impact from biotechnology. Different priorities have sprung from the "buzzword" biotechnology, frequently without taking long-term socioeconomic implications into account. Nevertheless, biotechnology presents extremely promising answers to a number of our issues through waste recycling, smart products, and benign synthesis. Biotechnology has enormous commercial potential—an incredible $1000 billion, or roughly an order of magnitude more than it does now! However, in order not to disappoint investors and taxpayers, we need to further develop our tools, especially for producing complex molecules for various applications.[1]

Active Pharmaceutical Ingredients (APIs) and excipients are the essential elements of pharmaceutical formulations, and the pharmaceutical industry is highly dependent on raw materials for medication development. Conventional approaches to generating pharmaceutical raw materials are frequently beset by inefficiencies, environmental issues, and difficulties in creating complex compounds.